Christopher M. Treleaven

Author

SynZyme Technologies (United States)

Also Known As

C. Treleaven, Christopher M Treleaven, Christopher M. Treleaven, Christopher Treleaven

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

SynZyme Technologies (United States)Beth Israel Deaconess Medical Center Harvard University Nationwide Children's Hospital The Ohio State University

About

Christopher M. Treleaven is an author at SynZyme Technologies (United States) specializing in medicine, neurology, and neuroscience.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	453
2	Social Sciences	3	3	215
3	Health Sciences	1	1	33
4	Natural Sciences	1	1	160
5	Cell Biology	1	1	86

Christopher M. Treleaven

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies S. Pablo Sardi, Jennifer Clarke, Catherine Viel, Proceedings of the National Academy of Sciences	2013	242
Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models S. Pablo Sardi, Catherine Viel, Jennifer Clarke, Proceedings of the National Academy of Sciences	2017	196
Silencing Mutant Huntingtin by Adeno-Associated Virus-Mediated RNA Interference Ameliorates Disease Manifestations in the YAC128 Mouse Model of Huntington's Disease Lisa M. Stanek, S. Pablo Sardi, Bryan Mastis, Human Gene Therapy GeneticsMolecular BiologyDisease Gene IdentificationMutant HuntingtinAntisense Therapy	2014	160
Delivery of AAV-IGF-1 to the CNS Extends Survival in ALS Mice Through Modification of Aberrant Glial Cell Activity James C. Dodge, Amanda M. Haidet, Wendy Yang, Molecular Therapy	2008	157
Glycosphingolipids are modulators of disease pathogenesis in amyotrophic lateral sclerosis James C. Dodge, Christopher M. Treleaven, Joshua Pacheco, Proceedings of the National Academy of Sciences	2015	130
Metabolic signatures of amyotrophic lateral sclerosis reveal insights into disease pathogenesis James C. Dodge, Christopher M. Treleaven, Jonathan A. Fidler, Proceedings of the National Academy of Sciences	2013	127
AAV4-mediated Expression of IGF-1 and VEGF Within Cellular Components of the Ventricular System Improves Survival Outcome in Familial ALS Mice James C. Dodge, Christopher M. Treleaven, Jonathan A. Fidler, Molecular Therapy	2010	124
Translational Fidelity of Intrathecal Delivery of Self-Complementary AAV9–Survival Motor Neuron 1 for Spinal Muscular Atrophy Marco A. Passini, Jie Bu, Amy M. Richards, Human Gene Therapy Knockout MouseNeuroregenerationSpinal Cord InjuryTranslational FidelityMedicine	2014	86
Intracerebroventricular infusion of acid sphingomyelinase corrects CNS manifestations in a mouse model of Niemann–Pick A disease James C. Dodge, Jennifer Clarke, Christopher M. Treleaven, Experimental Neurology Niemann–pick A DiseaseNeurodegenerative DiseasesIntracerebroventricular InfusionMolecular NeuroscienceNeurobiology Of Disease	2008	74
Glucocerebrosidase modulates cognitive and motor activities in murine models of Parkinson’s disease Edward Rockenstein, Jennifer Clarke, Catherine Viel, Human Molecular Genetics GeneticsNeurotransmitterNeurochemical BiomarkersSynaptic SignalingSocial Sciences	2016	55

Page 1